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Neuroblastoma and tooth abnormalities: a common history? 
 
 Neuroblastoma, a malignant tumor of the sympathetic nervous system and the most 
common extracranial solid tumor in childhood, arises from embryonic neural crest cells. 
Tooth development begins before birth and continues for 12-14 years with the development of 
the third molar for several years. Abnormal events that occur during odontogenesis give 
permanent damage. Whereas the impact of multimodal therapy including radiotherapy and 
chemotherapy is major in tooth development defects 
1
 we suggested that the particular 
association between neuroblastoma and the occurence of missing teeth is not necessary due to 
treatment effects but considered the hypothesis of a common underlying genetic defect 
because of common cell origin.  
 Dental data were obtained via medical or dental records for 12 patients treated for 
neuroblastoma at the Pediatric Oncology and Hematology department in the University 
Hospital of Rennes (France). Panoramic radiographs could be effectively performed in seven 
patients. We observed dental disturbances in 8 patients including oligodontia for five (table 
1). For 4 of them, we note the MYCN amplification in neuroblastoma cells. All but one were 
treated with one or more chemotherapeutic agents incriminated in tooth defect 
development and underwent a transplant. It would be attractive to incriminate the treatment 
effects as the cause of the dental abnormalities onset, because of the young age at NBL 
diagnosis contemporary to the most active dental development period. Furthermore, their 
treatment consists in multimodal therapy and used drugs commonly associated with dental 
defects in rodent experimentations
 2, 3
. In our study, oligodontia was also present in children 
under 3 years but this finding is not surprising because of the neuroblastoma median age of 2. 
Also we note the occurrence of both crown and eruption dental abnormalities in one patient 
(patient 11) treated with chemotherapy and autologous stem cell transplantation but at age 10. 
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While prevalence of dental agenesis is around 5% in general population 
4
, a recent study 
found a prevalence of 16.2% missing teeth in childhood cancer survivors treated from 0 to 7 
5
. 
Even if chemotherapy and total bone irradiation radiotherapy are likely to be etiological 
factors, it cannot be ruled out that regarding neuroblastoma, a developmental etiology could 
be considered. So intringuing, four of five patients with tooth agenesis presented a MYCN 
gene amplification. The proto-oncogene MYCN is mainly expressed during neural 
development 
6 and frequently amplified in advanced-stage neuroblastoma  associated with 
poor prognosis. MYCN might stimulate neuroblastoma cell proliferation by inhibiting negative 
regulators of the Wnt signaling 
7
. Furthermore, while germline mutations in the transcription 
factor PHOX2B gene have been reported in sporadic and familiar forms of neuroblastoma 
8, 9
, 
the MSX1 target is known to be associated with tooth agenesis
 10, 11
. Interestingly, MSX1, an 
important homeobox gene in embryonic neural crest development, was shown to be down 
regulated after inducible expression of PHOX2B 
12
. This PHOX2B target is involved in both 
embryonic developmental pathways Delta-Notch and Wnt 
12, 13
. Whereas links between 
cancer predisposition and dental abnormalities are well known for adulthood cancers 
involving disruption of the Wnt signalling (germline AXIN2 mutations, Gardner syndrome), 
we could emphasize that a dysregulation of the Wnt signaling pathway could take part in 
alteration of dental genesis and neuroblastoma tumorigenesis. 
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